Adobe Systems Inc vs Revvity Inc — how do they compare? Adobe Systems Inc trades at $256.21 (market cap $104.82B), while Revvity Inc trades at $115.96 (market cap $12.91B). The key difference: Adobe Systems Inc is far larger — about 8.1× Revvity Inc's market cap, and Revvity Inc pays a 0.24% dividend while Adobe Systems Inc pays none. Which is the better fit depends on your goals.
| ADBE | RVTY | |
|---|---|---|
Market Cap | $104.82B | $12.91B |
Volume | 5,187,646 | — |
Sector | Technology | Technology |
52-Week High | $367.46 | $117.75 |
52-Week Low | $193.41 | $82.26 |
Enterprise Value | $106.26B | $15.23B |
Dividend Yield | — | 0.24% |
Signals from Pluang's Aura AI — not financial advice
Adobe (ADBE) trades at $272.96, up 2.92% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 2025 revenue of $23.77B and net income of $7.13B, maintaining exceptional profitability margins. Recent earnings beats and accelerating revenue growth contrast with market concerns about AI competition and CEO transition.
Adobe presents a compelling value opportunity trading below analyst consensus targets despite strong operational performance. Key risks include AI disruption threats and ongoing leadership transition, while institutional accumulation and positive earnings momentum support potential upside. The stock's current valuation multiples appear attractive relative to growth prospects.
RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.
The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.
Trailing returns across standard periods
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →